Confidential mandate

IPO-Control Readiness Board Challenger — Advanced Manufacturing

Planned Hiring / New

IPO-Control Readiness Board Challenger mandate in Seoul, South Korea · Advanced Manufacturing Systems

A Seoul advanced manufacturer appoints a ten-month board challenger to test IPO finance-control readiness, evidence and leadership capacity without holding executive, audit, sponsor, listing or approval authority.

The mandate

The board repeatedly asks whether the group could operate as a listed company through a difficult quarter, rather than merely produce a prospectus on schedule. Close adjustments, forecast versions, related-party records, plant estimates and disclosure ownership still depend on a small number of executives. Advisers report workstream completion, while directors lack evidence that control and judgement survive routine pressure.

The challenger will reserve three days monthly for committee preparation, readiness-pack review and private sessions with Finance and Internal Audit, plus five Seoul meetings. A written response to a material control or disclosure-readiness event is due within two Korean business days. Remediation delivery, audit work, sponsor work or prospectus preparation requires a separate mandate.

The appointment lasts ten months from January 2027. At month eight, management must complete an unseen accelerated close, forecast miss and disclosure escalation for the committee. The board may approve one extension of up to three months for a named listing gate; renewal must be minuted, unused access expires and the role cannot become programme management.

The challenger has no line authority, executive authority, accounting-signing right, audit role, listing-sponsor responsibility, exchange mandate, disclosure approval or investment-banking function. Management owns readiness and reporting; auditors and advisers retain formal opinions. Advice cannot be represented as audit assurance, listing eligibility, prospectus approval or confirmation that an IPO should proceed.

Appointments or interests involving underwriters, auditors, reporting accountants, exchanges, investors, control advisers, law firms or competing issuers must be disclosed as conflicts. One unrelated board seat may continue with chair consent. Contingent compensation tied to filing, pricing, valuation, listing or adviser selection is incompatible with independent challenge.

Why the board wants this voice

Management and advisers are measured on completing the transaction, while the board must decide whether the institution can sustain listed-company discipline after celebration. It wants a former operator who has lived through public close and disclosure pressure, without adding another sponsor, audit provider or executive to the programme.

What you will own

  • Press directors to test close, consolidation, forecast, controls, related parties, disclosure and evidence retention as one operating cycle.
  • Challenge readiness ratings that count documented design without repeated operation by the people who will own it after listing.
  • Test finance leadership depth, succession, committee information, judgement escalation and capacity through peak transaction workload.
  • Frame scenarios for accelerated close, plant estimate failure, forecast miss, related-party discovery and disclosure correction.
  • Probe remediation dependencies across systems, data, advisers, audit evidence, policy decisions and local entities.
  • Examine whether investor metrics reconcile to books, approved definitions, forecast governance and consistent narrative evidence.
  • Coach directors to separate transaction timetable, control readiness, listing requirements and strategic appetite.

Candidate qualifications

  • Held senior CFO, controller or IPO finance-readiness authority through a public listing and subsequent reporting cycles.
  • Built repeatable close, control, forecast and disclosure governance across multi-site manufacturing operations and estimates.
  • Challenged readiness programmes whose documentation outpaced operating effectiveness, leadership depth or audit evidence.
  • Presented stop, delay and proceed choices to boards, sponsors, auditors and counsel without usurping their formal roles.
  • Governed related-party, alternative-performance and forward-looking information under investor and regulatory scrutiny.
  • Managed conflicts across banks, auditors, advisers and investors while protecting restricted listing and forecast evidence.

Non-negotiables

  • Can attend all five Seoul sessions and respond within two business days to a material readiness issue.
  • Will disclose underwriter, auditor, adviser, exchange, investor and issuer interests before programme access.
  • Accepts literal absence of line, executive, accounting-signing, audit, sponsor, exchange, disclosure and transaction authority.
  • Must evidence an IPO and later public reporting; transaction-adviser experience without operating ownership is insufficient.
  1. 49 words maximum. Describe an IPO readiness rating that changed after management had to operate the control under pressure.
  2. 49 words maximum. Which current bank, auditor, adviser, investor, exchange or issuer interests require disclosure?
  3. 49 words maximum. What unseen close and disclosure event would make you recommend delaying the listing gate?

This mandate is confidential. The client is named only under a mutual NDA, and your own record is never listed, sold or shown to a company under your name until you release it for this specific mandate.